Literature DB >> 19017934

Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2.

Daniel Ricklin1, Salome K Ricklin-Lichtsteiner, Maciej M Markiewski, Brian V Geisbrecht, John D Lambris.   

Abstract

Staphylococcus aureus expresses a highly diversified arsenal of immune evasion proteins, many of which target the complement system. The extracellular fibrinogen-binding protein (Efb) and the Efb homologous protein (Ehp) have previously been demonstrated to bind to C3 and inhibit complement activation and amplification. In this study we present the first evidence that Efb and Ehp are also capable of inhibiting the interaction of C3d with complement receptor 2 (CR2), which plays an important role in B cell activation and maturation. The C-terminal domain of Efb efficiently blocked this interaction both in surface plasmon resonance-based competition studies and cellular assays and prevented the CR2-mediated stimulation of B cells. Furthermore, analyses of the available structural data were consistent with a molecular mechanism that reflects both steric and electrostatic effects on the C3d-CR2 interaction. Our study therefore suggests that S. aureus may disrupt both the innate and adaptive immune responses with a single protein module.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017934      PMCID: PMC2673544          DOI: 10.4049/jimmunol.181.11.7463

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).

Authors:  L Clemenza; D E Isenman
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

2.  Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function.

Authors:  S E Henson; D Smith; S A Boackle; V M Holers; D R Karp
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

3.  Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

Authors:  M R Sarrias; S Franchini; G Canziani; E Argyropoulos; W T Moore; A Sahu; J D Lambris
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  Structure of complement receptor 2 in complex with its C3d ligand.

Authors:  G Szakonyi; J M Guthridge; D Li; K Young; V M Holers; X S Chen
Journal:  Science       Date:  2001-06-01       Impact factor: 47.728

5.  The electrostatic nature of C3d-complement receptor 2 association.

Authors:  Dimitrios Morikis; John D Lambris
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

Review 6.  The complement system in regulation of adaptive immunity.

Authors:  Michael C Carroll
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

7.  OKB7, a monoclonal antibody that reacts at or near the C3d binding site of human CR2.

Authors:  P E Rao; S D Wright; E F Westberg; G Goldstein
Journal:  Cell Immunol       Date:  1985-07       Impact factor: 4.868

8.  Lymphocyte binding of fluid phase mouse C3b.

Authors:  M Papamichail; M B Pepys
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

9.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Inhibition of complement activation by a secreted Staphylococcus aureus protein.

Authors:  Lawrence Y L Lee; Magnus Höök; David Haviland; Rick A Wetsel; Edward O Yonter; Peter Syribeys; John Vernachio; Eric L Brown
Journal:  J Infect Dis       Date:  2004-07-06       Impact factor: 5.226

View more
  28 in total

1.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

2.  Allosteric inhibition of complement function by a staphylococcal immune evasion protein.

Authors:  Hui Chen; Daniel Ricklin; Michal Hammel; Brandon L Garcia; William J McWhorter; Georgia Sfyroera; You-Qiang Wu; Apostolia Tzekou; Sheng Li; Brian V Geisbrecht; Virgil L Woods; John D Lambris
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 3.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

4.  Corruption of human follicular B-lymphocyte trafficking by a B-cell superantigen.

Authors:  Gwenoline Borhis; Muriel Viau; Gamal Badr; Yolande Richard; Moncef Zouali
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 5.  Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins.

Authors:  Brandon L Garcia; Kasra X Ramyar; Daniel Ricklin; John D Lambris; Brian V Geisbrecht
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 6.  Staphylococcus aureus in the Intensive Care Unit: Are These Golden Grapes Ripe for a New Approach?

Authors:  Georgia R Sampedro; Juliane Bubeck Wardenburg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

7.  Molecular characterization of endocarditis-associated Staphylococcus aureus.

Authors:  Cara Nethercott; Amanda N Mabbett; Makrina Totsika; Paul Peters; Juan C Ortiz; Graeme R Nimmo; Geoffrey W Coombs; Mark J Walker; Mark A Schembri
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

8.  A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family.

Authors:  Daniel Ricklin; Apostolia Tzekou; Brandon L Garcia; Michal Hammel; William J McWhorter; Georgia Sfyroera; You-Qiang Wu; V Michael Holers; Andrew P Herbert; Paul N Barlow; Brian V Geisbrecht; John D Lambris
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

Review 9.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

Review 10.  Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications.

Authors:  Alexander Laarman; Fin Milder; Jos van Strijp; Suzan Rooijakkers
Journal:  J Mol Med (Berl)       Date:  2010-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.